Approaches to the Modulation of Abdominal Pain
Despite their high prevalence and significant economic impact on the health care system, functional gastrointestinal disorders have evaded successful therapy. Conventional medical therapies are based on inadequate disease models, and the great majority of published treatment trials are flawed in the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1999-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1999/416576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545320870871040 |
|---|---|
| author | Emeran A Mayer Tony Lembo Lin Chang |
| author_facet | Emeran A Mayer Tony Lembo Lin Chang |
| author_sort | Emeran A Mayer |
| collection | DOAJ |
| description | Despite their high prevalence and significant economic
impact on the health care system, functional gastrointestinal
disorders have evaded successful therapy. Conventional
medical therapies are based on inadequate disease models, and the
great majority of published treatment trials are flawed in their design,
permitting no conclusions to be drawn about the true efficacy
of any particular treatment. During the past several years, a new,
comprehensive disease model based on alterations in brain-gut interactions
has rapidly evolved. Even though the precise mechanisms
and sites underlying these alterations remain incompletely
understood, plausible targets for the development of effective
pharmacological treatments are receptors on peripheral terminals
of visceral afferent nerves (opioids and serotonin), ion channels
and receptors on dorsal horn neurons within the spinal cord
(opioids, glutamate, calcitonin gene-related peptide and
neurokinin-1), and supraspinal targets in the brainstem within
the limbic system and in the prefrontal cortex (serotonin, catecholamines,
dopamine and acetylcholine). Regardless of the primary
pathophysiology underlying functional gastrointestinal
disorders (ie, central versus peripheral), different pharmacological
strategies targeted at different sites in the periphery or within the
central nervous system may become effective therapies in the future. |
| format | Article |
| id | doaj-art-a4b14ba659084bc0a09b2d644cbe9aba |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1999-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-a4b14ba659084bc0a09b2d644cbe9aba2025-02-03T07:26:07ZengWileyCanadian Journal of Gastroenterology0835-79001999-01-0113Suppl A66A70A10.1155/1999/416576Approaches to the Modulation of Abdominal PainEmeran A Mayer0Tony Lembo1Lin Chang2UCLA/CURE Neuroenteric Disease Program, Department of Medicine, Physiology and Brain Research Institute, UCLA School of Medicine, Los Angeles, California, USABeth Israel Deconnes Hospital, Boston, Massachusetts, USAUCLA/CURE Neuroenteric Disease Program, Department of Medicine, Physiology and Brain Research Institute, UCLA School of Medicine, Los Angeles, California, USADespite their high prevalence and significant economic impact on the health care system, functional gastrointestinal disorders have evaded successful therapy. Conventional medical therapies are based on inadequate disease models, and the great majority of published treatment trials are flawed in their design, permitting no conclusions to be drawn about the true efficacy of any particular treatment. During the past several years, a new, comprehensive disease model based on alterations in brain-gut interactions has rapidly evolved. Even though the precise mechanisms and sites underlying these alterations remain incompletely understood, plausible targets for the development of effective pharmacological treatments are receptors on peripheral terminals of visceral afferent nerves (opioids and serotonin), ion channels and receptors on dorsal horn neurons within the spinal cord (opioids, glutamate, calcitonin gene-related peptide and neurokinin-1), and supraspinal targets in the brainstem within the limbic system and in the prefrontal cortex (serotonin, catecholamines, dopamine and acetylcholine). Regardless of the primary pathophysiology underlying functional gastrointestinal disorders (ie, central versus peripheral), different pharmacological strategies targeted at different sites in the periphery or within the central nervous system may become effective therapies in the future.http://dx.doi.org/10.1155/1999/416576 |
| spellingShingle | Emeran A Mayer Tony Lembo Lin Chang Approaches to the Modulation of Abdominal Pain Canadian Journal of Gastroenterology |
| title | Approaches to the Modulation of Abdominal Pain |
| title_full | Approaches to the Modulation of Abdominal Pain |
| title_fullStr | Approaches to the Modulation of Abdominal Pain |
| title_full_unstemmed | Approaches to the Modulation of Abdominal Pain |
| title_short | Approaches to the Modulation of Abdominal Pain |
| title_sort | approaches to the modulation of abdominal pain |
| url | http://dx.doi.org/10.1155/1999/416576 |
| work_keys_str_mv | AT emeranamayer approachestothemodulationofabdominalpain AT tonylembo approachestothemodulationofabdominalpain AT linchang approachestothemodulationofabdominalpain |